New pill aims to quiet chronic hives without the itch

NCT ID NCT07684560

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental tablet called Alpha-0261 in people with chronic spontaneous urticaria (long-lasting hives) and in healthy volunteers. The study checks the drug's safety, how the body processes it, and whether it reduces hive activity and itching. Participants take the tablet or a placebo daily for several weeks while continuing their usual antihistamine treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Alpha-0261
What this could lead to
If successful, this could lead to a new oral treatment option for people with chronic hives that is easier to take than current therapies.
What could go wrong
This is an early Phase 1 trial with only 48 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA (CSU) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100044, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.